Biophytis S.A.

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics that slow degenerative processes and improve functional outcomes for patients with age-related diseases. Its lead drug candidate, BIO101, targets obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). The company has a collaboration agreement with AFM-Telethon for the development of BIO101 for DMD and an alliance with LynxKite Technologies Pte Ltd for AI-driven drug discovery for longevity therapies. Incorporated in 2006, Biophytis is headquartered in Paris, France.